OneSource Specialty Pharma Limited has announced a meeting of its Board of Directors scheduled for Wednesday, May 13, 2026. The primary objective of this session is to review and approve the company’s audited financial results, encompassing both standalone and consolidated performance, for the quarter and financial year ended March 31, 2026. This announcement signals a pivotal moment for investors as the company prepares to disclose its annual fiscal performance.
Board Meeting Overview
The management of OneSource Specialty Pharma Limited has confirmed that the Board of Directors will convene on May 13, 2026. During this meeting, the board will evaluate the comprehensive financial outcomes for the final quarter (Q4) and the full fiscal year concluded on March 31, 2026. Shareholders and market participants await these results to assess the company’s growth trajectory and operational efficiency over the past year.
Trading Window Update
In alignment with standard corporate governance and the company’s internal code of conduct regarding insider trading, the trading window for all designated persons has remained closed since April 01, 2026. This restriction is a precautionary measure to ensure transparency during the pre-earnings period. The trading window is scheduled to reopen 48 hours following the official announcement and dissemination of the financial results to the public.
Source: BSE
